PFM
ALBO

Privium Fund Management’s Albireo Pharma Inc ALBO Stock Holding History

Privium Fund Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,252
Closed -$6.5M – 166
2022
Q4 		$6.5M Hold
300,252
– – 2.47% 14
2022
Q3 		$5.62M Hold
300,252
– – 2.04% 15
2022
Q2 		$5.96M Sell
300,252
-51,553
-15% -$1.36M 1.98% 18
2022
Q1 		$10.5M Sell
351,805
-27,312
-7% -$800K 2.32% 9
2021
Q4 		$8.96M Buy
+379,117
New +$10.1M 1.78% 17

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Privium Fund Management's ALBO Position: Q1 2023 in Review

Privium Fund Management sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 300,252 shares — an estimated $6.5M sold.

Privium Fund Management first reported a position in ALBO in Q4 2021 and held it in 5 quarters. The position peaked at $10.5M in Q1 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Privium Fund Management reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Privium Fund Management sold 300,252 Albireo Pharma Inc shares in Q1 2023, an estimated $6.5M.
  • Privium Fund Management first reported a position in Albireo Pharma Inc in Q4 2021 and held it in 5 quarters.
  • Privium Fund Management's Albireo Pharma Inc position peaked at $10.5M in Q1 2022.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Privium Fund Management's 13F filing for Q1 2023, filed 3 May 2023.